References
- Harris N L, Jaffe E S, Stein H, Banks P M, Chan J KC, Cleary M L, et al. A revised European-American Classification of Lymphoid Neoplasm's: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
- Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
- de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–2947
- Chollet P, Bensmaine M A, Brienza S, Deloche C, Cure H, Caillet H, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065–1070
- Soulie P, Bensmaine A, Garrino C, Chollet P, Brain E, Fereres M, et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 1997; 33(9)1400–1406
- Velasquez W S, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
- Velasquez W S, McLaughlin P, Tucker S, Hagemeister F B, Swan F, Rodriguez M A, et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176
- Hickish T, Roldan A, Cunningham D, Mansi J, Ashley S, Nicolson V, et al. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer 1993; 68(3)559–604
- Raymond E, Faivre S, Woynarowski J M, Chaney S G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4–12
- Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte L M, et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 1999; 10: 1125–1128
- Chau I, Webb A, Cunningham D, Hill M, Rao S, Ageli S, et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 786–792
- Germann N, Brienza S, Rotarski M, Emile J F, Di Palma M, Musset M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999; 10: 351–354
- Addeo R, Caraglia M, Costanzo R, Faiola V, Montella L, Abbruzzese A, et al. Oxaliplatin/rituximab combination in the treatment og intermediate-low grade non-Hodgkin's lymphoma of elderly patients. Oncol Rep 2004; 12: 135–140
- Machover D, Delmas-Marsalet B, Misra S C, Gumus Y, Goldschmidt E, Schilf A, et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol 2001; 12: 1439–1443
- Carbone P P, Kaplas H S, Musshoff K, Smithers D W, Tubiana M. Report of the Committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1861
- Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1249
- Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Glick J H, et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high- grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994; 5: 91–95